AUG 25·SEC EDGARLow
RAAB MICHAEL sold $226K of ARDX
RAAB MICHAEL (President & CEO) sold 58,574 shares of ARDELYX, INC. (ARDX) at $3.86 ($0.23M total) across 4 trades on 2026-08-21.
StockNASDAQ · US · USDHealthcare · Biotechnology
$ARDX
ARDELYX, INC.
Price · $ARDXvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $ARDX in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $486K 21 txs
Williams Laura A4× · $41K
10b5-1 share of filings0%
Top stories · $ARDXMore →
AUG 21·stocktitan.net
Ardelyx (NASDAQ: ARDX) plans RSU tax-cover sale of 10,500 shares
Ardelyx (ARDX) filed a notice under Rule 144 for a potential sale of 10,500 shares by Laura A. Williams to cover taxes on vesting RSUs. The shares have an aggregate market value of $42,315. The sale is part of an automatic sell-to-cover mechanism for withholding taxes on 24,041 RSUs vesting in August 2026.
AUG 14·fool.com
Ardelyx (ARDX) Q2 2026 Earnings Call Transcript
Ardelyx (ARDX) reported Q2 2026 product revenue of $118.1 million, up 31% year over year, driven by IBSRELA ($86.2 million, +33%) and XPHOZAH ($31.9 million, +27%). Net loss was $16.7 million. The company revised 2026 guidance to $350-$370 million for IBSRELA and $110-$120 million for XPHOZAH, citing payer hurdles.
ARDX sentiment & insider activity
Recent ARDX coverage spans corporate actions, earnings and financial news.
In the last 30 days, ARDX insiders filed 21 SEC Form 4 transactions — no purchases and 21 sales ($486K). The most active reporter was Williams Laura A, Chief Patient Officer, with 4 filings.
What's driving ARDX
Insider sale by the chief executive may signal reduced confidence or portfolio rebalancing.
Minor dilution and supply increase; unlikely to move price materially.
Guidance reset increases near-term revenue risk while reaffirming XPHOZAH momentum and pushing key clinical readouts into 2H27.
The article links a sharp selloff in ARDX to a surge in put-heavy options activity, suggesting elevated downside hedging and bearish positioning.
Guidance reset tied to payer prior authorization and step edits is the core near-term risk driver for ARDX.
AlphAI scores every news story that mentions ARDX with an AI model for sentiment and relevance, and aggregates insider trades from ARDELYX, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $ARDX
Score
RAAB MICHAEL sold $226K of ARDX
RAAB MICHAEL (President & CEO) sold 58,574 shares of ARDELYX, INC. (ARDX) at $3.86 ($0.23M total) across 4 trades on 2026-08-21.
1 min readArdelyx (NASDAQ: ARDX) plans RSU tax-cover sale of 10,500 shares
Ardelyx (ARDX) filed a notice under Rule 144 for a potential sale of 10,500 shares by Laura A. Williams to cover taxes on vesting RSUs. The shares have an aggregate market value of $42,315. The sale is part of an automatic sell-to-cover mechanism for withholding taxes on 24,041 RSUs vesting in August 2026.
1 min read
Ardelyx (ARDX) Q2 2026 Earnings Call Transcript
Ardelyx (ARDX) reported Q2 2026 product revenue of $118.1 million, up 31% year over year, driven by IBSRELA ($86.2 million, +33%) and XPHOZAH ($31.9 million, +27%). Net loss was $16.7 million. The company revised 2026 guidance to $350-$370 million for IBSRELA and $110-$120 million for XPHOZAH, citing payer hurdles.
6 min readArdelyx options trading surges as stock falls 18%
According to exchange data compiled by Bloomberg and reported by Investing.com, Ardelyx Inc. options activity rose Friday morning to 11,147 contracts, with puts dominating (10,676). The October 16, 2026 $4 put led with 10,004 contracts. Ardelyx shares fell 18.4% to $3.98, and 3-month volatility rose to 74.93%.
2 min readWhy is Ardelyx stock plunging today?
Ardelyx (ARDX) shares fell about 16% pre-open after the company reported Q2 2026 results that missed Wall Street on revenue and EPS and cut full-year guidance. Q2 total product revenue was $118.1M, net loss $16.7M (-$0.07/share). Ardelyx lowered 2026 IBSRELA revenue guidance to $350–$370M and withdrew a prior XPHOZAH long-term target.
4 min readARDELYX, INC. (ARDX): Results of Operations and Financial Condition
ARDELYX, INC. (ARDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update Q2 2026 total product revenue of $118.1 million, reflecting 31% growth year-over-year IBSRELA Q2 2026 revenue growth of 33% year-over-year to $86.2 million XPHOZAH Q2 2026 revenue grow
5 min read
Claude AI Says Market is Ignoring Ardelyx (ARDX) Growth Catalysts
Insider Monkey’s “Claude Portfolio” account says Ardelyx (NASDAQ:ARDX) is undervalued versus an earnings turnaround. It cites a 58% rise in Ibsrela sales last quarter, a goal of $1B annual sales by 2029, and consensus EPS moving from breakeven in 2026 to about $0.52 in 2027. ARDX trades near $5.14; risks include delayed profits, dilution, and Medicare reimbursement pressure after an appeal loss for Xphozah.
6 min readARDELYX, INC. (ARDX): Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ARDELYX, INC. (ARDX) filed an SEC Form 8-K — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. ardx-20260629 0001437402 false 0001437402 2026-06-29 2026-06-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
3 min readARDELYX, INC. (ARDX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ARDELYX, INC. (ARDX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. ardx-20260616 0001437402 false 0001437402 2026-06-16 2026-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
3 min read
LADENBURG THALM/SH SH Begins Coverage on Ardelyx (NASDAQ:ARDX)
LADENBURG THALM/SH SH began coverage of Ardelyx (NASDAQ:ARDX), assigning a “buy” rating and a $16.00 price target, implying 179.43% upside from the stock’s current level. Other firms cited include Wedbush ($19), BTIG ($17), and HC Wainwright (raised to $18). Ardelyx reported Q1 EPS of -$0.15 and revenue of $94.47M.
5 min read